Literature DB >> 17346663

High yield, purity and activity of soluble recombinant Bacteroides thetaiotaomicron GST-heparinase I from Escherichia coli.

Yongde Luo1, Xinqiang Huang, Wallace L McKeehan.   

Abstract

Heparinase I from Flavobacterium heparinum, a source of diverse polysaccharidases, suffers from low yields, insufficient purity for structural studies and insolubility when expressed as a recombinant product in Escherichia coli that is devoid of glycosaminoglycan polysaccharidases. In this study, cDNA coding for the orthologue of F. heparinum heparinase I was constructed from genomic information from the mammalian gut symbiont Bacteroides thetaiotaomicron and expressed in E. coli as a fusion protein with GST at the N-terminus. This resulted in high yield (30 mg/g dry bacteria) of soluble product and facilitated one-step affinity purification to homogeneity. Purified heparinase I bearing the GST fusion exhibited a K(m) of 2.3 microM and V(max) of 42.7 micromol/min with a specific activity of 164 U/mg with heparin (average 12,000 Da) as substrate. The results indicate a 2-fold improvement in yield, specific activity and affinity for heparin as substrate over previous reports. The data suggest that the heparinase I from the gut symbiont exhibits a higher intrinsic affinity for heparin than that from F. heparinum. The purified GST fusion enzyme exhibited a requirement for Ca(2+) and a pH optimum between 6.7 and 7.3 that was similar to the enzyme freed of the N-terminal GST portion. Our study revealed that catalytic activity of heparinase I requires a reducing environment. The GST facilitated immobilization of heparinase I in solid phase either for clinical purposes or for structural studies in absence of interference by contaminating polysaccharidases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346663      PMCID: PMC1993911          DOI: 10.1016/j.abb.2007.01.029

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  37 in total

1.  Heparinase inhibits neovascularization.

Authors:  R Sasisekharan; M A Moses; M A Nugent; C L Cooney; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

2.  Purification of heparinase and heparitinase by affinity chromatography on glycosaminoglycan-bound AH-Sepharose 4B.

Authors:  N Ototani; M Kikuchi; Z Yosizawa
Journal:  Carbohydr Res       Date:  1981-02-02       Impact factor: 2.104

3.  Heparinase I from Flavobacterium heparinum. Mapping and characterization of the heparin binding domain.

Authors:  R Sasisekharan; G Venkataraman; R Godavarti; S Ernst; C L Cooney; R Langer
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

4.  Characterization of heparinase from an oral bacterium Prevotella heparinolytica.

Authors:  M Watanabe; H Tsuda; S Yamada; Y Shibata; T Nakamura; K Sugahara
Journal:  J Biochem       Date:  1998-02       Impact factor: 3.387

5.  Purification and characterization of heparin lyases from Flavobacterium heparinum.

Authors:  D L Lohse; R J Linhardt
Journal:  J Biol Chem       Date:  1992-12-05       Impact factor: 5.157

6.  Heparinase I from Flavobacterium heparinum: the role of the cysteine residue in catalysis as probed by chemical modification and site-directed mutagenesis.

Authors:  R Sasisekharan; D Leckband; R Godavarti; G Venkataraman; C L Cooney; R Langer
Journal:  Biochemistry       Date:  1995-11-07       Impact factor: 3.162

Review 7.  Enzymatic degradation of glycosaminoglycans.

Authors:  S Ernst; R Langer; C L Cooney; R Sasisekharan
Journal:  Crit Rev Biochem Mol Biol       Date:  1995       Impact factor: 8.250

8.  Heparinase I from Flavobacterium heparinum. Identification of a critical histidine residue essential for catalysis as probed by chemical modification and site-directed mutagenesis.

Authors:  R Godavarti; C L Cooney; R Langer; R Sasisekharan
Journal:  Biochemistry       Date:  1996-05-28       Impact factor: 3.162

9.  Heparinase production by Flavobacterium heparinum.

Authors:  P M Galliher; C L Cooney; R Langer; R J Linhardt
Journal:  Appl Environ Microbiol       Date:  1981-02       Impact factor: 4.792

10.  Expression in Escherichia coli, purification and characterization of heparinase I from Flavobacterium heparinum.

Authors:  S Ernst; G Venkataraman; S Winkler; R Godavarti; R Langer; C L Cooney; R Sasisekharan
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

View more
  6 in total

1.  Crystal structure of a bacterial unsaturated glucuronyl hydrolase with specificity for heparin.

Authors:  Yusuke Nakamichi; Bunzo Mikami; Kousaku Murata; Wataru Hashimoto
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

2.  Structural basis of heparan sulfate-specific degradation by heparinase III.

Authors:  Wei Dong; Weiqin Lu; Wallace L McKeehan; Yongde Luo; Sheng Ye
Journal:  Protein Cell       Date:  2012-07-21       Impact factor: 14.870

3.  Fusion protein strategy to increase expression and solubility of hypervariable region of VP2 protein of infectious bursal disease virus in Escherichia coli.

Authors:  Sahar Sadat Sedighzadeh; Mehdi Shamsara; Azar Shahpiri
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

4.  Structure-based engineering of heparinase I with improved specific activity for degrading heparin.

Authors:  Chuan Zhang; Bao-Cheng Yang; Wen-Ting Liu; Zhong-Yuan Li; Ya-Jian Song; Tong-Cun Zhang; Xue-Gang Luo
Journal:  BMC Biotechnol       Date:  2019-08-09       Impact factor: 2.563

5.  A highly active heparinase I from Bacteroides cellulosilyticus: Cloning, high level expression, and molecular characterization.

Authors:  Li-Wei Gao; Hong-Tao Zhu; Cai-Yun Liu; Zhi-Xiang Lv; Xiao-Man Fan; Ye-Wang Zhang
Journal:  PLoS One       Date:  2020-10-20       Impact factor: 3.240

6.  Facile synthesis of peanut-like Sn-doped silica nano-adsorbent for affinity separation of proteins.

Authors:  Mochou Gao; Qin Liu; Yuanyuan Xue; Bao Li; Xingchi Liu; Zhenzhu Shi; Nan Liu; Xueyan Zou
Journal:  RSC Adv       Date:  2022-02-08       Impact factor: 3.361

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.